Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Pluri Inc. (PLUR)

Adaptimmune Therapeutics PLC and Pluri Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Pluri Inc. are of similar size ($15.0M and $14.6M). Pluri Inc. grew revenue faster over the last twelve months: −24.0% against −54.0%. Adaptimmune Therapeutics PLC has the higher net margin (−262.5% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 17 metrics below, Adaptimmune Therapeutics PLC leads on 10 and Pluri Inc. on 7.

Valuation

Metric ADAPY PLUR Biotechnology median
P/E n/m n/m 10.60
P/S 0.08 11.89 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.08 31.96 9.02
Earnings yield (3,250.00%) (197.58%) (32.88%)
Free cash flow yield (3,648.13%) (167.21%) (23.13%)

Profitability

Metric ADAPY PLUR Biotechnology median
Gross margin 94.81% 44.59% 68.51%
Operating margin (427.75%) (2,454.53%) 0.00%
Net margin (262.46%) (2,344.59%) 0.00%
Free cash flow margin (294.49%) (1,988.48%) 0.00%
Return on equity (1,349.52%) 260.35% (51.96%)
Return on assets 0.00% (74.95%) (46.06%)
Return on invested capital 0.00% (526.92%) 0.00%

Growth

Metric ADAPY PLUR Biotechnology median
Revenue growth (TTM) (53.99%) (23.95%) 6.76%
EPS growth (last fiscal year) 142.86% 31.46% 29.88%
Revenue growth, 5-year CAGR 8.40% 113.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY PLUR Biotechnology median
Debt to equity (0.36) (1.62) 0.00
Current ratio 1.52 0.27 4.97
Net debt to EBITDA 0.47 (0.83) 1.01

Dividend

Metric ADAPY PLUR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY PLUR Biotechnology median
Market cap 14.55m 15.00m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack